誠志股份(000990.SZ):擬3.5億投資建設多功能車間及原料藥車間項目
格隆匯4月14日丨誠志股份(000990.SZ)公佈,公司為進一步拓展在生物製造領域的發展空間,擬通過全資子公司江西誠志生物工程有限公司(稱“誠志生物工程”)在江西鷹潭國家級高新區投資建設多功能車間及原料藥車間項目,預計項目總投資金額為3.5億。
公司在江西鷹潭的生物發酵工廠目前處於高負荷運營狀態,受制於裝置規模,亟需拓展新產品的發展空間。通過新建多功能車間及原料藥車間,引入高附加值原料及藥品產品以豐富整體產品線,進而將大幅增強公司在生物基材料領域的研發、生產實力。項目建成後,有利於公司打造高水平先進生物製造平台和合成生物技術創新基地,有利於完善技術創新體系建設和提升創新體系效能。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.